April 30th 2024
Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.
February 16th 2024
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Phase 3 Study Explores Pamrevlumab for Unresectable LAPC
February 17th 2021The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.
Phase 3 TRYbeCA-1 Trial in Second-Line Pancreatic Cancer Will Continue to Final Analysis
February 9th 2021Per a planned interim superiority analysis conducted by an independent data monitoring committee, a trial of Eryaspace will continue without modification with final results anticipated later this year.
Improved Risk Models Identify People at Higher than Normal Risk of Pancreatic Cancer
May 2nd 2020Researchers demonstrated that risk models that include established clinical, genetic, and circulating factors are better able to identify people at significantly higher than normal risk of pancreatic cancer over those using clinical factors alone.
Stereotactic Body Radiation Therapy Improves OS for Locally Advanced Pancreatic Cancer
March 10th 2020An international systematic review and meta-analysis indicated that stereotactic body radiation therapy compared to conventionally fractioned radiation therapy with concurrent chemotherapy may offer a modest improvement in OS with a more favorable toxicity profile.
Eileen M. O’Reilly, MD, on the Challenges of Treating Patients with Pancreatic Cancer
January 27th 2020The medical oncologist from Memorial Sloan Kettering Cancer Center discussed challenges in treating patients with pancreatic center, and also the challenge of obtaining effective drugs in the clinical setting.
Can PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes in Ovarian Cancer?
August 23rd 2019A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.